Nabriva Therapeutics Statistics
Total Valuation
Nabriva Therapeutics has a market cap or net worth of 646. The enterprise value is -1.64 million.
| Market Cap | 646 |
| Enterprise Value | -1.64M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nabriva Therapeutics has 3.23 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 3.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.03 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.13 |
Financial Position
The company has a current ratio of 0.38
| Current Ratio | 0.38 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -101.52 |
Financial Efficiency
Return on equity (ROE) is -602.21% and return on invested capital (ROIC) is -234.16%.
| Return on Equity (ROE) | -602.21% |
| Return on Assets (ROA) | -92.85% |
| Return on Capital (ROIC) | -234.16% |
| Revenue Per Employee | 757,872 |
| Profits Per Employee | -1.41M |
| Employee Count | 39 |
| Asset Turnover | 0.90 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.00% in the last 52 weeks. The beta is -6.99, so Nabriva Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | -6.99 |
| 52-Week Price Change | +100.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.57 |
| Relative Strength Index (RSI) | 37.40 |
| Average Volume (20 Days) | 882 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 11.55 |
Income Statement
In the last 12 months, Nabriva Therapeutics had revenue of 29.56 million and -55.05 million in losses. Loss per share was -17.90.
| Revenue | 29.56M |
| Gross Profit | -18.11M |
| Operating Income | -48.63M |
| Pretax Income | -54.22M |
| Net Income | -55.05M |
| EBITDA | -48.53M |
| EBIT | -48.63M |
| Loss Per Share | -17.90 |
Balance Sheet
The company has 2.18 million in cash and 540,000 in debt, giving a net cash position of 1.64 million or 0.51 per share.
| Cash & Cash Equivalents | 2.18M |
| Total Debt | 540,000 |
| Net Cash | 1.64M |
| Net Cash Per Share | 0.51 |
| Equity (Book Value) | -16.32M |
| Book Value Per Share | -5.05 |
| Working Capital | -16.25M |
Cash Flow
In the last 12 months, operating cash flow was -12.91 million and capital expenditures -115,000, giving a free cash flow of -13.02 million.
| Operating Cash Flow | -12.91M |
| Capital Expenditures | -115,000 |
| Free Cash Flow | -13.02M |
| FCF Per Share | -4.03 |
Margins
Gross margin is -61.26%, with operating and profit margins of -164.53% and -186.26%.
| Gross Margin | -61.26% |
| Operating Margin | -164.53% |
| Pretax Margin | -183.46% |
| Profit Margin | -186.26% |
| EBITDA Margin | -164.19% |
| EBIT Margin | -164.53% |
| FCF Margin | n/a |
Dividends & Yields
Nabriva Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.65% |
| Shareholder Yield | -34.65% |
| Earnings Yield | -8,522,291.02% |
| FCF Yield | -2,016,099.07% |
Stock Splits
The last stock split was on September 16, 2022. It was a reverse split with a ratio of 0.04.
| Last Split Date | Sep 16, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Nabriva Therapeutics has an Altman Z-Score of -103.22. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -103.22 |
| Piotroski F-Score | n/a |